Acurx Pharmaceuticals is a clinical stage biopharmaceutical company developing antibiotics for infections caused by bacteria. Co.'s research and development pipeline includes antibiotic candidates that target Gram-positive bacteria for oral and/or parenteral treatment of infections caused by Clostridium difficile, Enterococcus (including vancomycin-resistant strains), Staphylococcus (including methicillin-resistant strains), and Streptococcus (including antibiotic resistant strains). Co.'s antibiotic candidate, ibezapolstat, has a mechanism of action that targets the DNA polymerase IIIC enzyme. Co.'s pipeline, ACX-375C, an oral and parenteral treatment targeting Gram-positive bacteria. The ACXP average annual return since 2021 is shown above.
The Average Annual Return on the ACXP average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ACXP average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ACXP average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|